![](/images/graphics-bg.png)
Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients
المؤلفون المشاركون
Nguyen, Thi Hoa
Nguyen, Van Hung
Nguyen, Thanh Long
Qiuyin, Cai
Phung, Thi Huyen
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-09-10
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Background.
Obtaining tumor specimens and re-evaluating targeted markers is recommended, if possible, in breast cancer patients who relapsed after curative treatment.
The biomarker status changes in rebiopsied tumors have been demonstrated to have considerable clinical implications.
Objectives.
To identify the changes of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status between the primary and recurrent lesions.
Materials and Methods.
We conducted a study among 67 patients with recurrent breast cancer, recruited from January 2014 to September 2018 in the Vietnam National Cancer Hospital to compare ER, PR, and HER2 status between the primary and recurrent lesions.
For each patient, a specimen of their primary tumor and another specimen of recurrent lesions underwent pathological assessment.
Immunohistochemistry (IHC) was performed to determine ER, PR, and HER2 status in both specimens.
Results.
Biomarker status conversion rates (in both directions) between primary and recurrent tumors were 26.9% for ER, 38.8% for PR, and 22.4% for HER2.
Overall, IHC subtypes (hormone receptor positive, HER2 amplified, and triple-negative) changed in 25 out of 67 (37.3%) cases.
Conversion rates were not statistically significantly different between patients with different recurrent sites and times of recurrence.
Eight out of 13 initially triple-negative patients (61.5%) had a change to positive status of either ER, PR, or HER2.
Conclusion.
A substantial discordance in ER, PR, and HER2 status were observed between primary breast cancer tissues and recurrent lesions.
Rebiopsy could bring new therapeutic opportunities in the management of patients with recurrent breast cancer.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Nguyen, Thi Hoa& Nguyen, Van Hung& Nguyen, Thanh Long& Qiuyin, Cai& Phung, Thi Huyen. 2019. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients. BioMed Research International،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1127265
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Nguyen, Thi Hoa…[et al.]. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients. BioMed Research International No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1127265
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Nguyen, Thi Hoa& Nguyen, Van Hung& Nguyen, Thanh Long& Qiuyin, Cai& Phung, Thi Huyen. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1127265
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1127265
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)